

Article

Not peer-reviewed version

Pre-Wetting Reduces Blood Component Deposition on Polyvinyl Alcohol-Coated Poly- ϵ -Caprolactone Nanofiber Grafts

Masahiro Tsutsui , Takumi Yoshida , Daisuke Naruse , [Shingo Kunioka](#) , Yuta Kikuchi , Naohiro Wakabayashi , Hiroyuki Kamiya , [Kyohei Oyama](#) *

Posted Date: 19 May 2026

doi: 10.20944/preprints202605.1194.v1

Keywords: small-diameter vascular graft; nanofiber graft; poly- ϵ -caprolactone; polyvinyl alcohol; surface hydration; hemocompatibility



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC, OpenAlex.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Pre-Wetting Reduces Blood Component Deposition on Polyvinyl Alcohol-Coated Poly- ϵ -Caprolactone Nanofiber Grafts

Masahiro Tsutsui ¹, Takumi Yoshida ², Daisuke Naruse ³, Shingo Kunioka ¹, Yuta Kikuchi ¹, Naohiro Wakabayashi ¹, Hiroyuki Kamiya ¹ and Kyohei Oyama ^{1,*}

¹ Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan

² Life Materials Development Section, Human Life Technology Research Institute, Toyama Industrial Technology Research and Development Center, Toyama, Japan

³ Business Development section, Business Development and Quality Control Department, Iazaj Holdings Co., Ltd, Toyama, Japan

* Correspondence: koyama@asahikawa-med.ac.jp; Tel: +81-166-68-2494, Fax: +81-166-68-2499

Abstract

Hydrophilic surface modification is widely investigated as a strategy to improve the hemocompatibility of small-diameter vascular grafts. We previously developed a polyvinyl alcohol-coated poly- ϵ -caprolactone nanofiber graft (PVA-PCL graft) and showed that PVA coating improved graft hydrophilicity and mechanical properties. However, whether PVA coating provides an *in vivo* advantage over uncoated PCL grafts remains unclear. In addition, the influence of pre-implantation surface hydration on the function of hydrophilic grafts has not been fully examined. In this study, we first compared PVA-PCL and uncoated PCL grafts in a rat abdominal aorta implantation model and found no statistically significant difference in patency rate between the graft types. We then examined whether pre-wetting enhanced the anti-fouling function of the PVA coating. *In vitro* whole-blood flushing assays demonstrated that pre-wetting markedly reduced blood component deposition on PVA-PCL grafts. However, this effect did not translate into detectable improvements in patency or tissue regeneration in the rat model used in this study. These findings indicate that pre-wetting effectively enhances the *in vitro* anti-fouling behavior of PVA-PCL grafts and may serve as a simple strategy to optimize the functional surface state of hydrophilic coatings. Further studies are needed to determine whether this *in vitro* improvement can be translated into meaningful enhancement of graft performance *in vivo*.

Keywords: small-diameter vascular graft; nanofiber graft; poly- ϵ -caprolactone; polyvinyl alcohol; surface hydration; hemocompatibility

1. Introduction

Small-diameter surgical revascularization procedures, such as coronary artery bypass grafting (CABG) and distal bypass for lower-extremity peripheral arterial disease, rely primarily on autologous vessels. However, suitable autologous grafts are not always available because of poor vessel quality or insufficient length. Consequently, various vascular tissue engineering approaches have been explored to develop clinically applicable off-the-shelf small-diameter vascular grafts [1,2], nevertheless, the development of such grafts remains an unmet clinical need.

Synthetic polymers are widely investigated in vascular tissue engineering because of their advantages in cost, scalability, and stable supply [3]. Among them, poly- ϵ -caprolactone (PCL) is a biocompatible and biodegradable polymer, and electrospun PCL nanofibers have attracted attention as scaffold materials for small-diameter vascular graft fabrication. However, the hydrophobic nature of PCL is a major concern, as hydrophobic blood-contacting surfaces can promote adsorption of blood

components and platelet activation, potentially leading to thrombosis [4,5]. To address this disadvantage, we previously developed a PCL nanofiber graft coated with the hydrophilic polymer polyvinyl alcohol (PVA) (PVA–PCL graft) with the aim of improving hemocompatibility. In our previous report, PVA coating improved the mechanical properties and handling of the PCL graft, increased surface hydrophilicity, and suppressed platelet adsorption in experiments using platelet-rich plasma [6]. Moreover, the PVA–PCL graft demonstrated patency for 8 weeks with autologous tissue-like regeneration in a rat implantation model [6]. However, despite these improvements in material properties, it remains unclear whether PVA coating provides a measurable *in vivo* advantage over an uncoated PCL graft, particularly in terms of graft patency and tissue regeneration in an animal model.

In addition to the material composition itself, graft performance may depend on the pre-implantation condition [7,8]. Hydrophilic materials are known to reduce non-specific adsorption of biological components, including proteins and platelets, and this anti-fouling behavior has been attributed to the formation and retention of a hydration layer at the material–blood interface [9,10]. From this perspective, a PVA-coated surface may function optimally when it is sufficiently hydrated at the time of blood contact. If a simple and clinically feasible preparation step, such as pre-wetting, could maximize the hemocompatibility conferred by a hydrophilic coating, this strategy could improve translational feasibility without adding complexity to graft fabrication.

Therefore, the aim of this study was (1) to evaluate the *in vivo* efficacy of PVA coating by directly comparing the performance of PVA–PCL and uncoated PCL grafts in terms of patency, and (2) to determine whether a simple pre-wetting preparation enhances the functional performance of the PVA–PCL graft.

2. Materials and Methods

2.1. Nanofiber Graft Preparation

The PVA-coated PCL nanofiber graft (PVA–PCL graft) was prepared as previously described [6]. Briefly, a PCL nanofiber sheet was electrospun from a 10% (w/v) poly(ϵ -caprolactone) solution (PCL; Mw 80,000; Sigma-Aldrich) dissolved in a mixture of *N,N*-dimethylformamide (DMF) and tetrahydrofuran (THF) (3:7, w/w) under the following conditions: an applied voltage of 20 kV, a tip-to-collector distance of 20 cm, a flow rate of 1.7 mL/h, and a collector rotation speed of 20 rpm. The resulting nanofiber sheet was cut into 20-mm-wide strips and wrapped around a 1-mm-diameter polytetrafluoroethylene (PTFE) mandrel to form three layers. After removal of the PTFE mandrel, the resulting tubular scaffold was defined as the uncoated PCL nanofiber graft (PCL graft). To generate the PVA-coated graft, a coating solution was prepared by mixing a commercially available 5% (w/v) PVA aqueous solution with ethanol and water at a weight ratio of 1:1:1. The resulting solution was slowly injected into the PCL graft. Excess solution was removed by flushing with an empty syringe, and the graft was dried overnight at room temperature to obtain the PVA–PCL graft.

2.2. Nanofiber Graft Implantation and Harvest *In Vivo*

All animal experiments were approved by the Institutional Animal Care and Use Committee. Male Wistar rats (8–10 weeks old; Charles River, Japan) were anesthetized with 5% isoflurane for induction and maintained with 2–3% isoflurane delivered via a small-animal anesthesia machine. A midline laparotomy was performed to expose the abdominal aorta, and the inferior vena cava was carefully dissected free from the aorta. The infrarenal aorta was clamped just below the left renal artery and above the aortic bifurcation. The aorta was transected and replaced with a nanofiber graft (PCL graft or PVA–PCL graft) (inner diameter, 1 mm; length, ~10 mm). The graft was anastomosed to the aorta using an end-to-end technique using running 10-0 polypropylene sutures. After removal of the clamps, hemostasis was confirmed and the abdominal incision was closed. Rats were allowed free access to food and water, and no antiplatelet or anticoagulant medications were administered during the follow-up period.

At the study endpoint, graft patency was assessed under general anesthesia by confirming pulsatile blood flow distal to the graft. The grafts were then flushed with PBS and perfusion-fixed with 4% paraformaldehyde (PFA) via intracardiac infusion through the left ventricular apex, followed by graft explantation.

2.3. *In Vitro Whole-Blood Flushing Assay*

With approval from the Institutional Review Board of Asahikawa Medical University (approval no. 21166), peripheral blood (20 mL) was collected from three healthy volunteers after written informed consent. Blood was collected into standard K2EDTA-coated blood collection tubes to prevent coagulation. Samples were kept at room temperature and used within 1 h of collection. PVA–PCL grafts (inner diameter, 3 mm; length, 20 mm) were prepared and assigned to either a pre-wet (wet) or non-pre-wet (dry) condition. For the wet condition, grafts were immersed in Milli-Q water for 10 min immediately before testing; dry grafts were used without pre-wetting. Human whole blood (2.5 mL) was flushed through each graft three times using a 2.5-mL syringe. The grafts were then flushed three times with phosphate-buffered saline (PBS) using a 20-mL syringe. After flushing, grafts were opened longitudinally to expose the luminal surface for macroscopic inspection and then fixed in 2% glutaraldehyde for subsequent scanning electron microscopy.

2.4. *Histological Analysis*

Explant grafts were further fixed overnight in 4% PFA. After washing with PBS, grafts were cut longitudinally into two halves, each containing both the proximal and distal anastomotic native vessels. Samples were embedded in optimal cutting temperature (OCT) compound (Sakura Finetek) and stored at -80°C . Frozen specimens were sectioned at 5 μm thickness using a cryostat at -20°C and mounted on glass slides.

Hematoxylin and eosin (H&E) staining was performed using a standard protocol to evaluate tissue morphology and cellular repopulation of the graft lumen. Briefly, sections were washed in PBS for 5 min to remove OCT, stained with hematoxylin solution (FUJIFILM) for 4 min, and rinsed under running water for 6 min. Sections were then stained with 1% eosin solution (FUJIFILM) for 2 min and rinsed three times with 70% ethanol. Slides were mounted with Marinol 750 (Muto Pure Chemicals).

For immunofluorescence staining, heat-induced antigen retrieval was performed in Tris–EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween 20, pH 9.0) at 98°C for 1 h. Sections were blocked with 1% bovine serum albumin (BSA) in PBS and incubated overnight at 4°C with primary antibodies against CD31 (R&D Systems, AF3628; 1:200) and α -smooth muscle actin (Cell Signaling Technology, #56856; 1:250). Alexa Fluor 488–conjugated anti-goat IgG (Thermo Fisher Scientific, A-11055) and Alexa Fluor 555–conjugated anti-mouse IgG (Thermo Fisher Scientific, A-31570) were applied as secondary antibodies for 1 h at room temperature. Nuclei were counterstained with Hoechst 33342 (FUJIFILM, 346-07951).

Images of H&E- and immunofluorescence-stained sections were acquired using an all-in-one fluorescence microscope (Keyence, BZ-X810).

2.5. *Scanning Electron Microscopy Analysis*

For conductive staining, graft specimens fixed in 2% glutaraldehyde (Section 2.3) were immersed in 1% tannic acid in 0.1 M phosphate buffer (PB) for 1 h, rinsed in PB for 1 h, and post-fixed in 1% osmium tetroxide in 0.1 M PB for 1 h. Specimens were then dehydrated through a graded ethanol series (70%, 80%, 90%, and 95%; 30 min each). After dehydration, ethanol was replaced with tert-butyl alcohol (1 mL, three times). Specimens were freeze-dried using a vacuum dryer (VD-400F; TAITEC). The dried specimens were mounted on aluminum bases, coated with gold using an ion-sputter coater (JEC-550; JEOL), and observed using a scanning electron microscope (JSM-6610LA; JEOL).

2.6. Statistical Analysis

All statistical analyses were performed with EZR version 1.54 [11]. All nominal variables were analyzed with Fisher's exact test. $p < 0.05$ was considered as statistically significant.

3. Results

3.1. Comparison of PVA-Coated and -Non-Coated PCL Graft

We previously reported that PVA coating increases the hydrophilicity and improves the mechanical properties of electrospun PCL nanofiber vascular grafts (PCL grafts). However, the *in vivo* efficacy of PVA-coated PCL grafts (PVA-PCL grafts) compared with uncoated PCL grafts has not been evaluated. Therefore, we examined whether PVA coating provides advantages in patency *in vivo* by directly comparing PVA-PCL and PCL grafts (Figure 1).

PCL and PVA-PCL grafts (inner diameter, 1 mm; length, 10 mm) were implanted into the abdominal aorta of rats ($n = 5$ per group) and harvested at 8 weeks post-implantation for analysis (Figure 1A). The patency rate was 60% (3/5) in the PCL group and 80% (4/5) in the PVA-PCL group, with no statistically significant difference between groups ($p = 1.0$) (Figure 1B). Macroscopic and histological analyses revealed no obvious differences between groups; both graft types exhibited a patent lumen and tissue regeneration along the graft wall (Figure 1C, D). Collectively, PVA coating did not confer a detectable advantage over uncoated PCL grafts in terms of patency in this model.




Figure 1

Figure 1. In vivo comparison of PVA-PCL and PCL grafts. (A) Schematic of the experimental design. PVA-PCL and PCL grafts of the same size were prepared and implanted into the abdominal aorta of rats ($n = 5$ per group). Grafts were harvested at 8 weeks for assessment of patency and autologous tissue regeneration. (B) **Patency rate at 8 weeks.** Patency was evaluated by confirming pulsatile blood flow distal to the graft and by macroscopic inspection. (C) **Macroscopic images of explanted grafts.** Representative cross-sectional (upper) and longitudinal (lower) views are shown. Scale bars, 2 mm. (D) **Hematoxylin and eosin (H&E) staining of**

explanted grafts. Representative low-magnification (left) and high-magnification (right) images are shown. Scale bars, 500 μm (left) and 50 μm (right).

3.2. Pre-Wetting Reduces Blood Component Deposition on PVA–PCL Grafts

In our previous study, PVA coating increased the hydrophilicity of PCL grafts. Hydrophilic surfaces are generally associated with reduced non-specific adsorption of biocomponents, and this behavior has been attributed to the formation of a hydration layer at the blood–material interface[12]. However, in the present study, PVA–PCL grafts did not show a statistically significant improvement in patency compared with uncoated PCL grafts (Figure 1). Because the hemocompatible function of a hydrophilic coating may depend on its hydration state at the time of blood contact, we hypothesized that pre-wetting of PVA–PCL grafts would enhance their anti-fouling performance. To test this possibility, we first examined the effect of pre-wetting on blood component deposition on PVA–PCL grafts in vitro.

PVA–PCL grafts (inner diameter, 3 mm; length, 20 mm) were prepared. Grafts were either immersed in Milli-Q water for 10 min (wet group) or used without pre-wetting (dry group) (Figure 2A). Human whole blood (2.5 mL) was flushed through each graft three times using a syringe, after which the grafts were opened longitudinally for evaluation of luminal deposition (Figure 2A). Macroscopic observation revealed clear differences between groups: the luminal surface of dry grafts appeared red-stained, suggesting deposition of erythrocyte-rich components, whereas wet grafts showed minimal visible staining (Figure 2B). Scanning electron microscopy further supported these observations. Dry grafts exhibited extensive deposition of granular material and adherent blood cells, whereas wet grafts showed markedly reduced surface deposits (Figure 2C). Taken together, these results indicate that pre-wetting reduces blood component deposition on PVA–PCL grafts in vitro.




Figure 2

Figure 2. Effect of pre-wetting on blood component deposition on PVA–PCL grafts in vitro. (A) Schematic of the experimental design. PVA–PCL grafts were either immersed in double-distilled water for 10 min (wet group) or used without pre-wetting (dry group). Human whole blood (2.5 mL) was flushed through each graft three times using a syringe. Grafts were then opened longitudinally to evaluate luminal deposition, and the luminal surface was examined. (B) Macroscopic images of graft lumens after blood flushing. Representative images of the luminal surfaces of wet and dry grafts are shown. Scale bars, 10 mm. (C) Scanning electron

microscopy of graft lumens after blood flushing. Representative SEM images of the luminal surfaces of wet and dry grafts are shown. Scale bars, 5 mm.

3.3. Pre-Wetting Has no Effect on In Vivo Graft Performance

Because pre-wetting reduced blood component deposition on PVA-PCL grafts in vitro (Figure 2), we next evaluated whether pre-wetting improves graft performance in vivo using a rat abdominal aorta implantation model (Figure 3). PVA-PCL grafts (inner diameter, 1 mm; length, 10 mm) were either immersed in phosphate-buffered saline (PBS) for 5 min before implantation (wet group) or implanted without pre-wetting (dry group). Grafts were implanted into the abdominal aorta of rats and harvested at 8 weeks post-implantation for assessment of patency and tissue regeneration (Figure 3A). The patency rate was 80% (4/5) in both groups, with no statistically significant difference ($p = 1.0$) (Figure 3B). Macroscopic observation of explanted grafts revealed no obvious differences between groups; the luminal surface appeared white and smooth in both wet and dry conditions (Figure 3C). Immunofluorescence analyses further demonstrated comparable autologous vessel-like regeneration in both groups, including endothelial coverage and smooth muscle cell positive neointimal formation along the graft wall (Figure 3C).

Thus, although pre-wetting reduced blood component deposition in vitro, this preparation step did not result in detectable improvements in patency or tissue regeneration in this rat implantation model.




Figure 3

Figure 3. Effect of pre-wetting on PVA-PCL graft performance in vivo. (A) Schematic of the experimental design. PVA-PCL grafts were either immersed in phosphate-buffered saline (PBS) for 5 min before implantation

(wet group) or implanted without pre-wetting (dry group). Grafts were implanted into the abdominal aorta of rats ($n = 5$ per group) and harvested at 8 weeks for assessment of patency and autologous tissue regeneration. **(B) Patency rate at 8 weeks.** Patency was evaluated by confirming pulsatile blood flow distal to the graft and by macroscopic inspection. **(C) Macroscopic and immunofluorescence analyses of explanted grafts.** Representative macroscopic images are shown (upper left in each group). Scale bars, 2 mm. Representative immunofluorescence images at low magnification (upper middle and right) and high magnification (lower) are shown. CD31 (green), α -smooth muscle actin (red), and nuclei (blue). Scale bars, 100 μm (low magnification) and 1 mm (high magnification).

4. Discussion

In the present study, we performed two sequential evaluations to clarify the functional significance of PVA coating and pre-wetting of electrospun PCL nanofiber grafts. Although no functional advantage was detected in the rat implantation model used in this study, a key finding was that pre-wetting clearly reduced blood component deposition on PVA–PCL grafts in vitro, supporting the concept that optimization of the surface hydration state can enhance the anti-fouling function of the PVA coating.

4.1. Pre-Wetting as Optimization of the Functional Surface State of PVA Coating

Hydrophilic surfaces are generally considered to suppress the non-specific adsorption of blood components, including proteins, platelets, and blood cells, and therefore have been widely investigated for application to blood-contacting medical devices [13]. One proposed mechanism underlying this effect is the formation of intermediate water at the material–blood interface, which may reduce direct contact between biological components and the polymer surface [9,12]. On the basis of these concepts, we previously developed a PVA-coated PCL nanofiber graft and demonstrated that PVA coating increased the hydrophilicity of the PCL graft [6]. In the present study, we further considered that, although PVA is itself a hydrophilic material, its anti-fouling potential might be more effectively expressed when the coated surface is already hydrated before exposure to blood. Indeed, pre-wetting clearly reduced blood component deposition on PVA–PCL grafts in vitro (Figure 2). Although the present study did not directly characterize the interfacial water structure of the PVA-coated surface, our findings are consistent with the idea proposed in previous studies that intermediate water suppresses the adsorption of biological components [9,12]. Thus, the anti-fouling effect observed in pre-wet PVA–PCL grafts may reflect more effective expression of the intrinsic hemocompatible properties of the PVA coating through prior surface hydration. This concept may not be limited to PVA–PCL grafts alone. Rather, simple pre-wetting may represent a practical strategy for maximizing the hemocompatibility of other hydrophilic materials or surface coatings, a possibility that should be examined in future studies across a broader range of biomaterial systems.

4.2. Discrepancy in PVA–PCL Graft Performance Between In Vitro and In Vivo Evaluations

Despite the clear in vitro effect of pre-wetting, no improvement in patency or autologous vessel-like regeneration was observed in vivo. One possible explanation is that the difference between pre-wet and non-pre-wet PVA–PCL grafts may have been reduced during the surgical procedure itself. Even grafts implanted without intentional pre-wetting may have become hydrated through exposure to the operative field, blood, or surrounding moisture, such that the effective difference in hydration state between the two groups at the time of blood contact was smaller in vivo than in the controlled in vitro setting. In addition, we speculate that the rat abdominal aorta implantation model itself may not be sufficiently sensitive to detect modest differences in antithrombogenic performance. Because the rat abdominal aorta is a short, high-flow, high-pressure vascular segment, grafts may remain patent as long as the anastomosis is technically adequate. Consistent with this interpretation, previous studies using this model have frequently reported favorable patency rates for small-diameter vascular grafts [10,14,15]. Although this observation does not directly prove a limitation of

the model, it may suggest that this model is less suitable for discriminating subtle functional differences in graft hemocompatibility.

Therefore, we interpret the absence of a detectable in vivo benefit in the present study as not necessarily indicating that PVA coating or pre-wetting is ineffective. Rather, the present findings suggest that a gap remains between simplified in vitro evaluations and in vivo graft performance. Establishing evaluation systems in which in vitro and in vivo findings more closely correspond will be important for more accurately assessing the functional value of surface modification and pre-conditioning strategies.

5. Conclusions

In conclusion, pre-wetting reduced blood component deposition on PVA–PCL nanofiber grafts in vitro; however, this effect did not translate into improved in vivo outcomes. Further studies using refined in vitro assays and alternative in vivo evaluation strategies and animal models will be required to clarify why the in vitro anti-fouling effect was not reflected in vivo. Elucidating the determinants of this in vitro–in vivo discrepancy will enable rational optimization of surface and pre-conditioning strategies to more reliably predict and improve the long-term patency of clinically translatable small-diameter vascular grafts.

Author Contributions: MT performed data collection, analysis and manuscript writing. Y.K. and S.K. assisted with data collection. KO performed data analysis, manuscript writing, and coordination of the study. TY and DN performed material preparation. NW established the methodology of graft implantation in rats. HK conceived the study and reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by JSPS KAKENHI, Grant Number JP22K08911 to MT, JP21K20938 to MT, JP20KK0200 to KO and JP19K09258 to HK.

Institutional Review Board Statement: The animal study protocol was approved by the Institutional Animal Care and Use Committee of Asahikawa Medical University (approval no. 22-178, R5-087, R6-094, R7-042). The human blood collection protocol was approved by the Institutional Review Board of Asahikawa Medical University (approval no. 21166).

Informed Consent Statement: Written informed consent was obtained from all healthy volunteers who provided blood samples in this study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of interest: DN is employed by Iazaj Holdings Co., Ltd. No financial support was received from Iazaj Holdings Co., Ltd. The remaining authors declare no conflicts of interest.

References

1. Leal BBJ, Wakabayashi N, Oyama K, Kamiya H, Braghirolli DI, Pranke P: **Vascular Tissue Engineering: Polymers and Methodologies for Small Caliber Vascular Grafts.** *Front Cardiovasc Med* 2020, 7:592361.
2. Nakayama Y, Iwai R, Terazawa T, Tajikawa T, Umeno T, Kawashima T, Nakashima Y, Shiraishi Y, Yamada A, Higashita R *et al*: **Pre-implantation evaluation of a small-diameter, long vascular graft (Biotube®) for below-knee bypass surgery in goats.** *J Biomed Mater Res B Appl Biomater* 2022, 110(11):2387-2398.
3. Tara S, Rocco KA, Hibino N, Sugiura T, Kurobe H, Breuer CK, Shinoka T: **Vessel bioengineering.** *Circ J* 2014, 78(1):12-19.
4. Leszczak V, Popat KC: Improved in vitro blood compatibility of polycaprolactone nanowire surfaces. *ACS Appl Mater Interfaces* 2014, 6(18):15913-15924.
5. Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI: Medical device-induced thrombosis: what causes it and how can we prevent it? *J Thromb Haemost* 2015, 13 Suppl 1:S72-81.

6. Wakabayashi N, Yoshida T, Oyama K, Naruse D, Tsutsui M, Kikuchi Y, Koga D, Kamiya H: Polyvinyl alcohol coating prevents platelet adsorption and improves mechanical property of polycaprolactone-based small-caliber vascular graft. *Front Cardiovasc Med* 2022, 9:946899.
7. Shojaee M, Wood KB, Moore LK, Bashur CA: Peritoneal pre-conditioning reduces macrophage marker expression in collagen-containing engineered vascular grafts. *Acta Biomater* 2017, 64:80-93.
8. Sameti M, Shojaee M, Saleh BM, Moore LK, Bashur CA: Peritoneal pre-conditioning impacts long-term vascular graft patency and remodeling. *Biomater Adv* 2023, 148:213386.
9. Tanaka M, Mochizuki A: Clarification of the blood compatibility mechanism by controlling the water structure at the blood-poly(meth)acrylate interface. *J Biomater Sci Polym Ed* 2010, 21(14):1849-1863.
10. Valence S, Tille JC, Chaabane C, Gurny R, Bochaton-Piallat ML, Walpoth BH, Möller M: **Plasma treatment for improving cell biocompatibility of a biodegradable polymer scaffold for vascular graft applications.** *Eur J Pharm Biopharm* 2013, 85(1):78-86.
11. Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 2013, 48(3):452-458.
12. Tanaka M, Morita S, Hayashi T: Role of interfacial water in determining the interactions of proteins and cells with hydrated materials. *Colloids Surf B Biointerfaces* 2021, 198:111449.
13. Kuchinka J, Willems C, Telyshev DV, Groth T: **Control of Blood Coagulation by Hemocompatible Material Surfaces-A Review.** *Bioengineering (Basel)* 2021, 8(12).
14. Dokuchaeva AA, Mochalova AB, Timchenko TP, Podolskaya KS, Pashkovskaya OA, Karpova EV, Ivanov IA, Filatova NA, Zhuravleva IY: **In Vivo Evaluation of PCL Vascular Grafts Implanted in Rat Abdominal Aorta.** *Polymers (Basel)* 2022, 14(16).
15. Pan Y, Zhou X, Wei Y, Zhang Q, Wang T, Zhu M, Li W, Huang R, Liu R, Chen J *et al*: **Small-diameter hybrid vascular grafts composed of polycaprolactone and polydioxanone fibers.** *Sci Rep* 2017, 7(1):3615.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.